This was not unexpected since B16-OVA does not induce tumor-specific T cells, and for antibodies which block inhibitory pathways to be effective, there is a requirement for pre-existing anti-tumor CD8+ T cells at the tumor site [55]. The gene discussed is CD8A; the disease is neoplasm.